RBD-BRIDGE™

Rare Bone Disease Imaging Biomarker Initiative (RBD-IBI)

771 Rare Bone Diseases. ~5% of All Birth Defects. Millions Affected Worldwide.

Most still lack a fit-for-purpose quantitative imaging biomarker.

Scroll to discover
The clinical conundrum

A fragility fracture is a clear sign that something is wrong. But when bone density and structural scans can look completely normal, doctors, patients and families are left asking the same critical question:

What are we missing?

This initiative exists to help solve that exact conundrum.

RBD-IBI was created to help close this diagnostic gap — through better measurement of skeletal pathology.

To advance quantitative imaging biomarkers that objectively measure skeletal pathology in Rare Bone Diseases.

Research. Hope. Earlier Answers.

The consequences

The consequences of the RBD measurement gap.

What happens when objective measurement is missing.

Delayed or missed diagnosis
Disease misclassification
Inadequate objective quantification of skeletal pathology
Difficulty monitoring disease progression
Uncertainty about treatment response
Insensitive or biologically mismatched clinical-trial endpoints
Difficulty demonstrating therapeutic benefit
Slower therapeutic development
Delayed translation of promising research into patient care

Therapies are advancing. Measurement must advance with them.

The consequences affect patients and families, clinicians, researchers, pharmaceutical and biotechnology developers, investors and funders, regulators, governments and healthcare systems.

The right therapy also needs the right measurement.

A promising therapy may be evaluated using an endpoint that is familiar, available and well validated in another skeletal disease, yet insufficiently sensitive or biologically matched to the Rare Bone Disease pathology the therapy is intended to change.

Investing early in the right biomarker can protect a much larger investment in drug development and clinical trials.

The fundamental problem

The fundamental measurement blind spot holding back imaging-biomarker development in RBDs.

The flawed assumption

Established measures of bone health are often assumed to be fit for purpose in Rare Bone Diseases.

The biological difference

RBDs arise from diverse biological causes and can produce skeletal pathologies fundamentally different from osteoporosis.

The measurement gap

A tool developed to measure osteoporosis may not measure the pathology driving a Rare Bone Disease.

Most established quantitative bone measurements were developed primarily around osteoporosis — particularly bone loss and related structural deterioration. Because these tools are widely accepted as measures of “bone health”, they can be carried into Rare Bone Disease research with the implicit assumption that they measure skeletal health more generally.

But different bone diseases can fail for different biological reasons. A measurement can be technically excellent for the biological target it was designed to assess, yet still be biologically mismatched to the pathology of the RBD being studied.

A technically excellent measurement can still be biologically wrong for the disease being studied.

That assumption can hide the measurement gap itself.

If an appropriate skeletal biomarker is assumed to already exist, there is less reason to first define the disease-relevant pathology or invest in developing the measurement actually needed. Existing tools may therefore continue to be selected, adapted and validated in RBDs without first establishing that they adequately measure the biological abnormality driving the disease.

Do not ask first

“Which bone test do we already have?”

Ask first

“What skeletal pathology does this disease produce — and how should it be measured?”

This is the conceptual shift at the heart of RBD-IBI.

A familiar measurement is not necessarily a fit-for-purpose measurement.

Measuring the wrong biological target more precisely does not solve the RBD measurement gap.

“You cannot understand what you cannot objectively measure. Dedicated imaging biomarkers are the foundation of understanding, innovation, and better care for Rare Bone Diseases.”

Rare Bone Diseases Deserve the Same Imaging Biomarker Innovation that Transformed Osteoporosis.

Scientific principles

The first two RBD-IBI principles.

Two principles give a clear introduction to the RBD-IBI scientific thinking — without reproducing the complete Consensus Framework.

Principle 1

RBDs are not osteoporosis — think beyond osteoporosis-derived measurements.

Osteoporosis-derived measurements were developed primarily around bone loss and related structural deterioration. Many RBDs arise from fundamentally different skeletal pathologies and therefore may not be adequately represented or detected by osteoporosis-derived measurements.

“Do not inherit a measurement paradigm from another disease. RBDs are not osteoporosis, and forcing rare skeletal pathology into an osteoporosis-derived measurement framework is a fundamental measurement error.”

This does not make established technologies poor technologies. They may measure the skeletal properties they were designed to assess extremely well. What should not be assumed is that those same properties necessarily represent the disease-defining pathology of every Rare Bone Disease.

Principle 2

In RBDs, the biological cause and pathophysiological mechanism must be defined before selecting the technology or device used to study the disease.

The biological cause of an RBD and the pathophysiological mechanism by which it produces skeletal abnormality determine the biological target that an imaging biomarker must measure. The biological target should not be reverse-engineered from the capabilities, availability, convenience or familiarity of an existing technology.

“Biology and pathophysiology define what must be measured; technology determines how it is measured — not what should be measured.”

We don’t treat a label. We don’t treat a property. We treat the pathology — so we should measure the pathology.

Once the need is recognised

Why rarity makes the problem harder to solve.

Once the need for a fit-for-purpose biomarker is recognised, Rare Bone Diseases present a second challenge: the patients, expertise, imaging and evidence required to develop and validate that biomarker are often dispersed and fragmented.

  1. Individual RBD populations are small
  2. RBDs are biologically heterogeneous
  3. Patients and expertise are geographically dispersed
  4. Imaging datasets are fragmented across institutions and studies
  5. Archived imaging and datasets may be difficult to identify and access
  6. Disease-specific validation cohorts are often inadequate
  7. Genetic, biochemical, pathological, imaging, natural-history and clinical evidence are frequently disconnected
  8. Disease-by-disease biomarker development can duplicate scarce infrastructure, data and resources

Overcoming the limitations of rarity is a core RBD-IBI mission

RBD-IBI is designed not only to identify the need for better biomarkers, but also to address the practical limitations that have made those biomarkers difficult to develop and validate in Rare Bone Diseases.

Where different Rare Bone Diseases are demonstrated to share the same biologically defined skeletal pathology, RBD-IBI seeks to determine whether those diseases can form a scientifically justified group for shared biomarker development and validation.

This can allow patients, imaging, datasets, evidence, expertise, controls, infrastructure and validation resources to be brought together where scientifically appropriate, rather than repeatedly rebuilding the same development pathway disease by disease.

Rare diseases may be individually small. Shared pathology can create a larger scientific opportunity.

The measurement blind spot creates the need. Rarity makes solving it difficult. RBD-IBI is designed to address both.

The RBD-IBI response

Start with the biology. Measure the pathology. Then choose the technology.

RBD-IBI proposes a biology-first approach in which the skeletal pathology produced by the disease is defined before selecting the technology used to measure it.

Where etiologically distinct Rare Bone Diseases are demonstrated to share the same clinically relevant skeletal pathology, RBD-IBI asks whether that Shared Skeletal Pathology can support shared measurement, evidence generation and validation across those diseases.

This is important because the RBD-IBI approach addresses both major problems:

First

Identify what actually needs to be measured.

Second

Use shared biology, where scientifically justified, to overcome some of the limitations imposed by rarity.

How RBD-IBI works

The RBD-IBI pathway, step by step.

Every visitor should be able to follow the logic — whether or not they already know RBD-IBI terminology. The scientific terms are shown underneath each step.

  1. Start with the rare bone disease

    Rare Bone Disease

    What is happening in the skeleton?

  2. Identify the skeletal abnormality

    What is wrong in the skeleton?

    Defined Skeletal Pathology

  3. Ask whether other rare bone diseases share it

    Is the same pathology shared by other RBDs?

    Shared Skeletal Pathology (SSP)

  4. Define which diseases can be studied together

    Which diseases can be studied together?

    RBD–SSP Group Population

  5. Bring together the imaging, data & evidence

    What imaging and evidence already exist?

  6. Develop a way to measure the pathology

    How can the pathology be measured?

    Shared Imaging Biomarker

  7. Test that the measurement works

    Does the measurement work reliably?

    Fit-for-Purpose Validation for a Defined Context of Use

  8. Put the measurement to use

    Can it improve research, trials and care?

    Research Clinical Trials Therapeutic Development Regulatory Science Clinical Care

Shared pathology enables shared measurement.
Shared measurement enables shared evidence generation.

RBD-BRIDGE™ is the interactive digital platform being developed to operationalise this framework. Find out more

Initiatives & projects

RBD-IBI initiatives & projects.

Elements of the RBD-IBI framework, delivered as focused projects — each currently in development.

International Consensus Framework to Address the Imaging-Biomarker Gap in RBDs

Project 001

In Development Consensus Review — Open

Develop and publish an international scientific framework to address the imaging-biomarker gap in Rare Bone Diseases by establishing standards for identifying disease-relevant skeletal pathology and for the discovery, development, validation and fit-for-purpose use of quantitative imaging biomarkers.

This is the foundational RBD-IBI scientific project addressing the measurement gap described throughout the homepage.

Review the consensus draft

Available to approved members.

Explore the framework

RBD-BRIDGE™

Rare Bone Disease Biomarker Research, Imaging, Data & Global Evidence Platform

Project 002

In Development

An interactive, expert-governed digital platform connecting patients, clinicians, researchers and industry. It integrates RBD knowledge, imaging repositories, shared biomarker development, clinical trials and emerging therapies.

Learn about RBD-BRIDGE™

Coming Soon

Project 003

Coming Soon

Future RBD-IBI initiative.

Coming Soon

Project 004

Coming Soon

Future RBD-IBI initiative.

RBD-BRIDGE™ — Project 002

The digital platform that operationalises the RBD-IBI framework.

RBD-BRIDGE™ is Project 002 within RBD-IBI - not a separate organisation. It is the interactive, expert-governed operational platform that sits behind the RBD-IBI framework to support structured participation, evidence contribution and implementation workflows.

The RBD-IBI website provides information, education and public engagement. RBD-BRIDGE™ enables patients and families, clinicians, researchers and partners to contribute imaging, relevant clinical information or lived experience under appropriate consent and governance; register interest in research and validation studies; contribute priorities and questions; participate in structured consultations or surveys; and connect appropriately with RBD-IBI research and biomarker programmes.

Platform under development.

Enter RBD-BRIDGE™
Research. Hope. Earlier Answers.
About RBD-IBI

Research. Hope. Earlier Answers.

RBD-IBI is an independent, international, clinician-led and platform-independent scientific initiative uniting patients, clinicians, researchers, academia, industry, regulators, governments, NGOs and funders to advance fit-for-purpose quantitative imaging biomarkers for Rare Bone Diseases.

Our Charter, mission, vision and broader scientific principles — and what Research. Hope. Earlier Answers. means in practice — are set out in full on our About page.

Read about our Charter, mission and principles
For patients & families

We are here for people living with rare bone diseases — not just for the science.

If you or someone you love is affected by a rare bone disease, you may have questions and no easy answers yet. Our promise is simple: clear, trustworthy information in plain language, and routes to the help that exists.

What we aim to offer here

Planned with patient partners in mind — this is what we aim to offer here:

  • Plain-language explanations of rare bone diseases
  • Guidance on finding specialist care and support (in development)
  • What taking part in research involves
  • Support for families and carers
The whole RBD ecosystem

Built for everyone working to change the outlook for Rare Bone Diseases.

RBD-IBI is relevant to, and welcomes participation from, the full international Rare Bone Disease ecosystem.

  • Patients & Families
  • Patient Organisations & NGOs
  • Clinicians
  • Researchers
  • Academia
  • Imaging Scientists
  • Pharmaceutical & Biotechnology Companies
  • Technology Developers
  • Investors & Funders
  • Regulators
  • Governments & Policymakers
  • Healthcare Institutions
  • Other Scientific & Clinical Collaborators
Resources

Publications, imaging & data resources.

View all resources

Evidence library

Reviews, guidelines and publications — curated here as the evidence grows.

Browse publications

Imaging & data resources

Governed imaging and datasets — consent-based, ethically reviewed and accessible under clear conditions — ready for rigorous secondary research.

Access the resources

Practical guides

Protocols and processes designed to help sites run studies to the shared standard.

See the guides
Sustainability

Built to last, not built to fade.

A durable funding and governance model is designed to keep the initiative useful long after individual programmes end — protecting data, relationships and trust.

Read more
Key figures

International interest to date.

Interest in RBD-IBI has already been expressed by researchers and clinicians in several countries. Verified figures will be published here as partnerships, studies and resources are confirmed — openly, and never invented.

3 Countries with interest expressed to date Australia • Germany • Canada
Partners & Collaborators

Building an international RBD imaging-biomarker network.

RBD-IBI is bringing together researchers, clinicians, imaging scientists, patients, academic institutions and industry partners interested in advancing quantitative imaging biomarkers for rare bone diseases.

Get involved

Help shape what comes next.

Whether you lead research, deliver care or live with RBD - there is a way in. The website provides information and education; use RBD-BRIDGE™ for structured participation and collaboration.